Anti-Human TGFB1/TGF-beta-1 Antibody (SAA0443) from ProteoGenix; catalogue ARO-A15514; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-Human TGFB1/TGF-beta-1 Antibody (SAA0443) is a monoclonal antibody that specifically targets and binds to the transforming growth factor beta 1 (TGFB1) protein in humans. This antibody is used in various research studies and has potential therapeutic applications due to its ability to inhibit the activity of TGFB1, a key cytokine involved in numerous physiological and pathological processes.
The Anti-Human TGFB1/TGF-beta-1 Antibody is a monoclonal antibody, meaning it is produced by a single clone of immune cells. It is a type of immunoglobulin G (IgG) antibody, which is the most abundant type of antibody in the human body. The antibody has a Y-shaped structure, with two heavy chains and two light chains held together by disulfide bonds. The variable regions of the antibody are responsible for binding to the TGFB1 protein, while the constant regions determine its effector functions.
The primary activity of Anti-Human TGFB1/TGF-beta-1 Antibody is its ability to bind to and neutralize the activity of TGFB1. TGFB1 is a multifunctional cytokine that plays a crucial role in cell growth, differentiation, and immune response. It is also involved in wound healing, tissue repair, and inflammation. However, overexpression of TGFB1 has been linked to various diseases, including cancer, fibrosis, and autoimmune disorders. By binding to TGFB1, the antibody prevents its interaction with its receptors and inhibits downstream signaling pathways, thereby reducing its activity.
In addition to neutralizing TGFB1, Anti-Human TGFB1/TGF-beta-1 Antibody also has other effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms involve the recruitment and activation of immune cells, such as natural killer cells and macrophages, to target and destroy cells expressing TGFB1.
As a therapeutic target, Anti-Human TGFB1/TGF-beta-1 Antibody has shown potential in the treatment of various diseases. In cancer, the overexpression of TGFB1 promotes tumor growth, invasion, and metastasis. By inhibiting TGFB1 activity, the antibody can potentially slow down tumor progression and enhance the effectiveness of other cancer treatments. In fact, preclinical studies have shown promising results in using Anti-Human TGFB1/TGF-beta-1 Antibody as a monotherapy or in combination with other therapies in various types of cancer, including breast, lung, and pancreatic cancer.
The antibody also has potential therapeutic applications in fibrotic diseases, such as pulmonary fibrosis and liver fibrosis. TGFB1 is a key mediator of fibrosis, promoting the excessive production and deposition of extracellular matrix proteins. By blocking TGFB1, Anti-Human TGFB1/TGF-beta-1 Antibody can potentially prevent or reverse fibrosis and improve organ function.
In addition to its therapeutic potential, Anti-Human TGFB1/TGF-beta-1 Antibody is also widely used in research studies. It is a valuable tool for studying the role of TGFB1 in various physiological and pathological processes. The antibody can be used in various techniques, such as ELISA, western blotting, and immunohistochemistry, to detect and quantify TGFB1 levels in biological samples.
In summary, Anti-Human TGFB1/TGF-beta-1 Antibody is a monoclonal antibody that specifically targets and neutralizes the activity of TGFB1, a key cytokine involved in various diseases. Its potential therapeutic applications in cancer and fibrotic diseases, as well as its use as a research tool, make it a valuable asset in the scientific community.
ProteoGenix catalogue number ARO-A15514. For research use only.
Target: TGFB1/TGF-beta-1; Clonality: Monoclonal Antibody; Reactivity: Anti-Human Monoclonal Antibody, Human; Applications: Flow Cyt, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Anti-Human Monoclonal Antibody | ||||||||
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
